Nuvilex Gets Update from CK41 on purEffect Launch Plan

CHERRY HILL, N.J., May 28 /PRNewswire-FirstCall/ -- Nuvilex, Inc. (OTC Bulletin Board: NVLX), an emerging healthcare consumer products company, announced today that Charleston Kentrist 41 Direct, Inc. (CK41), the Company's joint venture marketing partner for purEffect(TM), a four-step acne treatment system, has updated its product launch plans.

The previously announced mid-May 2009 launch has been pushed back to allow Mr. Savage, CK41's new Chief Executive Officer, to impart his experience and knowledge into the purEffect formulation, packaging design and marketing plan. Presently, five thousand (5,000) newly formulated and designed purEffect packages are in production. Additionally, the competitive landscape for over-the-counter acne treatment products has significantly changed requiring new thinking on how to effectively market and price purEffect. CK41 is revising its Internet marketing plans and is in the process of negotiating a new mass media promotion campaign, which will include either renegotiated existing or new celebrity endorsements. Assuming current plans stay on target, purEffect should be ready for market by the end of June 2009.

"Mr. Savage is a renowned expert in cosmetics brand development and marketing. We believe in his ability and have confidence he will launch purEffect the right way," stated Martin Schmieg, Chairman and CEO of Nuvilex, Inc. "purEffect is a viable product that can and will compete successfully in the $1 billion over-the-counter acne treatment market. The six-week delay from the planned mid-May launch is insignificant compared to the invaluable contributions that Mr. Savage is making to the product, its market launch and commercial success. Everything that is good is worth waiting for."

About purEffect

purEffect is a comprehensive, all-in-one acne treatment solution that is designed to cleanse, tone, and heal the skin. purEffect combines a unique blend of ingredients that work to help maintain a radiant, blemish-free complexion. Benzoyl peroxide, the active ingredient in purEffect, is the safest, most widely recommended ingredient used to treat acne. Benzoyl peroxide serves as an antibacterial compound, minimizes inflammation that is associated with acne, and helps to prevent the formation of new acne deposits. One kit of purEffect includes a 4 fl. oz. bottle of Purifying Cleanser (Step 1), a 4 fl. oz. bottle of Electrolyte Toner (Step 2), a 2 fl. oz. bottle of Intense Repair Lotion (Step 3), and a 0.5 fl. oz. container of Healing Cream (Step 4). Steps 1 through 3 are to be used in order--once in the morning and once at night--while Step 4 can be used twice daily at any time. Step 4 is also compatible with sunblocks, sunscreens, and other skin creams. The Purifying Cleanser and Intense Repair Lotion each contain 2.5% benzoyl peroxide while the Electrolyte Toner contains ingredients such as Hamamelis virginiana (witch hazel) and glycolic acid that are known to help revitalize the skin. The Healing Cream contains natural oils that are derived from plants and helps to repair skin that is damaged by acne (or acne-associated inflammation).

About CK41 Direct, Inc. CK41 Direct, Inc. is a leading producer of direct response infomercial campaigns. Combining 50 years of expertise in network television and direct marketing know-how, the principals and directors of CK41 learned the direct response TV industry from the ground up. This experience has taught CK41 how both conventional and unconventional marketing strategies can excel a direct response television campaign.

About Nuvilex, Inc.

Nuvilex is an emerging healthcare consumer products company with a portfolio of aesthetics, dermatology, environmental and nutraceutical products. The company's focus is on developing, licensing and commercializing healthcare products that address the health needs of consumers worldwide. In March 2009, Nuvilex merged with Freedom2 Holdings, Inc., a diversified skin products technology company serving the fast-growing body art, aesthetic, cosmetic and skin therapy markets. More information is available at: http://www.nuvilex.com/ or http://www.freedom2inc.com/.

Safe Harbor Statement

Statements contained in this presentation that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. The forward-looking statements are made based on information available as of the date hereof, and the Company assumes no obligation to update such forward-looking statements. Forward-looking statements are sometimes identified by words such as "intends", "anticipates", "believes", "expects", and "hopes" and involve a number of risks and uncertainties that could cause the Company's actual results to differ materially from projected results. All parties are cautioned that such forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from those in these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the Company's products and services, the planned share exchange with Freedom2 Holdings, Inc., our ability to secure additional financing, and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.

Investor Relations Contacts: Blair Barnes Senior Vice President and Chief Financial Officer Nuvilex, Inc. Ph: 856-433-6088 Email: [e-mail] Stephanie Carrington/Amy Glynn The Ruth Group Ph: 646-536-7017/7023 Email: [e-mail] Email: [e-mail] Press Contact: Pat Arcand Arcand & Madison Ph: 617-576-7777 Email: [e-mail]

Nuvilex, Inc.

CONTACT: Investor Relations: Blair Barnes, Senior Vice President and
Chief Financial Officer, Nuvilex, Inc., [phone], [e-mail];
Stephanie Carrington, [phone], [e-mail], or Amy
Glynn, [phone], [e-mail], both of The Ruth Group; or
Press: Pat Arcand, Arcand & Madison, [phone], [e-mail]

Web Site: http://www.nuvilex.com/